Targeted Oncology retweeted
An infographic has been added to this open access paper
link.springer.com/article/10…
Targeted Oncology retweeted
Our Medicine Matters Oncology journal club highlights publications each month from our key titles @TargetOncology, @AdvancesTherapy and more.
This Post is from an account that no longer exists. Learn more
Targeted Oncology retweeted
Recently published in Targeted Oncology, an independently written Adis Drug Evaluation on gilteritinib in relapsed or refractory FLT3-mutated acute myeloid leukaemia. Read the article here: link.springer.com/article/10…
#leukemia
Targeted Oncology retweeted
Exciting #news for Oncology and Therapy...
The journal is now indexed on #PubMed
All articles from and including June 2018 are now indexed on the site: buff.ly/2OS26lA
#cancer #oncology #openaccess
Targeted Oncology retweeted
Brain Penetration of #Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive #NSCLC link.springer.com/article/10…
Targeted Oncology retweeted
Call For Papers
Oncology and Therapy has an active call for papers. Publish your original research, reviews, patient related papers and more.
Fully #openaccess with rapid timelines, brought to you by Adis (part of #SpringerHealthcare)
springer.com/journal/40487/ for more info
Targeted Oncology retweeted
The Adis Team will be attending #ISMPPEU20 next week and are really looking forward to meeting you. Please come and visit us at Stand 2 and be in with the chance to win an Amazon Kindle!
#Adis #Publishing #openaccess
Targeted Oncology retweeted
Model-Based #Cost #Effectiveness Analysis of #Panitumumab Plus FOLFIRI for the Second-Line #Treatment of #Patients with Wild-Type Ras #Metastatic #Colorectal #Cancer buff.ly/2ZWQsuj
Targeted Oncology retweeted
Read our newly published Letters to the Editor:
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China buff.ly/2FrCZRE
And the response letter: buff.ly/37HyheU
Targeted Oncology retweeted
Just published: The Effect of #Rifampin on the #Pharmacokinetics and Safety of #Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants buff.ly/2Q21p9k
Targeted Oncology retweeted
#Observational Study of Sequential #Afatinib and #Osimertinib in #EGFR Mutation-Positive #NSCLC: #Patients Treated with a 40-mg Starting Dose of Afatinib buff.ly/36YAySv
Targeted Oncology retweeted
Huge news for #bladdercancer with new agent (EV) approved! More to come! Good to look ORR & outcomes with EV in pts with FGFR alterations! Field moving forward @BladderCancerUS @IBCG_BladderCA @IBCN1997 @bladderau @ArjunBalarMD @MattGalsky @FDAOncology @ERPlimackMD @apolo_andrea
Targeted Oncology retweeted
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic #UrothelialCarcinoma link.springer.com/article/10… #ADC
Targeted Oncology retweeted
Published this year in Targeted Oncology, results of pre-specified and post hoc analyses of the phase III ARAMIS trial with an accompanying Plain Language Summary buff.ly/35fVIuj #openaccess #esmo19 #darolutamide #prostratecancer #plainlanguagesummary #PLS
Targeted Oncology retweeted
Please join Network Pharma’s ‘Meet the publishers’ panel on 4th December, where Caroline Halford (Adis Digital Publishing Manager) will be co-hosting a session on current and future trends in medical publishing #medcomms
Register here: zoom.us/webinar/register/WN_…
Targeted Oncology retweeted
Online now: Clinicians’ #Perspectives on Cure in Adult Patients with Acute Lymphoblastic #Leukemia with Minimal Residual Disease: A Delphi Study
Read the associated Plain Language Summary for this article below, and access the full article online here: buff.ly/320zmfq
Targeted Oncology retweeted
Indirect Treatment Comparison of #Nivolumab Versus Observation or #Ipilimumab as Adjuvant Therapy in Resected #Melanoma Using Pooled Clinical Trial Data buff.ly/2UcyDEB
Targeted Oncology retweeted
Existing and Emerging #Biomarkers for Immune #Checkpoint #Immunotherapy in Solid #Tumors buff.ly/2zel6me
Targeted Oncology retweeted
Maintenance Versus Intermittent Strategies in the Treatment of #Metastatic #Colorectal #Cancer:A Meta-Analysis from Another Angle buff.ly/2KY8vcz
























